...
search icon
fgen-img

FibroGen Inc, Common Stock

FGEN

NSQ

$0.4899

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$49.37M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
578.57K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.73
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.18 L
$2.93 H
$0.4899

About FibroGen Inc, Common Stock

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameFGENSectorS&P500
1-Week Return-7.58%3.54%-0.58%
1-Month Return-7.83%7.51%1.89%
3-Month Return63.96%-0.85%3.24%
6-Month Return-56.26%-1.67%10.09%
1-Year Return-71.35%5.2%22.09%
3-Year Return-96.62%13.08%35.68%
5-Year Return-98.83%44.4%83.47%
10-Year Return-98.42%111.45%200.41%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue256.58M176.32M235.31M140.73M147.75M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":68.72,"profit":true},{"date":"2021-12-31","value":91.71,"profit":true},{"date":"2022-12-31","value":54.85,"profit":true},{"date":"2023-12-31","value":57.59,"profit":true}]
Cost of Revenue1.15M8.87M12.87M20.28M18.85M[{"date":"2019-12-31","value":5.66,"profit":true},{"date":"2020-12-31","value":43.73,"profit":true},{"date":"2021-12-31","value":63.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.94,"profit":true}]
Gross Profit255.43M167.45M222.44M120.45M128.90M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":65.56,"profit":true},{"date":"2021-12-31","value":87.08,"profit":true},{"date":"2022-12-31","value":47.16,"profit":true},{"date":"2023-12-31","value":50.47,"profit":true}]
Gross Margin99.55%94.97%94.53%85.59%87.24%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":95.4,"profit":true},{"date":"2021-12-31","value":94.95,"profit":true},{"date":"2022-12-31","value":85.97,"profit":true},{"date":"2023-12-31","value":87.64,"profit":true}]
Operating Expenses344.74M359.33M510.97M421.48M398.11M[{"date":"2019-12-31","value":67.47,"profit":true},{"date":"2020-12-31","value":70.32,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.49,"profit":true},{"date":"2023-12-31","value":77.91,"profit":true}]
Operating Income(89.31M)(191.88M)(288.53M)(301.02M)(281.81M)[{"date":"2019-12-31","value":-8931400000,"profit":false},{"date":"2020-12-31","value":-19188000000,"profit":false},{"date":"2021-12-31","value":-28853000000,"profit":false},{"date":"2022-12-31","value":-30102500000,"profit":false},{"date":"2023-12-31","value":-28181500000,"profit":false}]
Total Non-Operating Income/Expense25.34M6.10M(4.31M)12.31M(7.73M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":24.07,"profit":true},{"date":"2021-12-31","value":-16.99,"profit":false},{"date":"2022-12-31","value":48.58,"profit":true},{"date":"2023-12-31","value":-30.49,"profit":false}]
Pre-Tax Income(76.64M)(188.93M)(290.68M)(294.87M)(286.87M)[{"date":"2019-12-31","value":-7664200000,"profit":false},{"date":"2020-12-31","value":-18893100000,"profit":false},{"date":"2021-12-31","value":-29068300000,"profit":false},{"date":"2022-12-31","value":-29486900000,"profit":false},{"date":"2023-12-31","value":-28686700000,"profit":false}]
Income Taxes328.00K360.00K347.00K358.00K3.00K[{"date":"2019-12-31","value":91.11,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":96.39,"profit":true},{"date":"2022-12-31","value":99.44,"profit":true},{"date":"2023-12-31","value":0.83,"profit":true}]
Income After Taxes(76.97M)(189.29M)(291.03M)(295.23M)(286.87M)[{"date":"2019-12-31","value":-7697000000,"profit":false},{"date":"2020-12-31","value":-18929100000,"profit":false},{"date":"2021-12-31","value":-29103000000,"profit":false},{"date":"2022-12-31","value":-29522700000,"profit":false},{"date":"2023-12-31","value":-28687000000,"profit":false}]
Income From Continuous Operations(76.97M)(189.29M)(290.02M)(293.65M)(294.18M)[{"date":"2019-12-31","value":-7697000000,"profit":false},{"date":"2020-12-31","value":-18929100000,"profit":false},{"date":"2021-12-31","value":-29002300000,"profit":false},{"date":"2022-12-31","value":-29365400000,"profit":false},{"date":"2023-12-31","value":-29417500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(76.97M)(189.29M)(291.03M)(295.23M)(284.23M)[{"date":"2019-12-31","value":-7697000000,"profit":false},{"date":"2020-12-31","value":-18929100000,"profit":false},{"date":"2021-12-31","value":-29103000000,"profit":false},{"date":"2022-12-31","value":-29522700000,"profit":false},{"date":"2023-12-31","value":-28423200000,"profit":false}]
EPS (Diluted)(0.96)(2.13)(3.14)(3.14)(2.80)[{"date":"2019-12-31","value":-96,"profit":false},{"date":"2020-12-31","value":-213,"profit":false},{"date":"2021-12-31","value":-314,"profit":false},{"date":"2022-12-31","value":-314,"profit":false},{"date":"2023-12-31","value":-280,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

FGEN
Cash Ratio 0.69
Current Ratio 1.28
Quick Ratio 1.16

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

FGEN
ROA (LTM) -26.55%
ROE (LTM) -1015.79%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

FGEN
Debt Ratio Lower is generally better. Negative is bad. 1.76
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.76

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

FGEN
Trailing PE NM
Forward PE 61.35
P/S (TTM) 0.28
P/B 53.83
Price/FCF NM
EV/R 0.27
EV/Ebitda NM
PEG NM

FAQs

What is FibroGen Inc share price today?

FibroGen Inc (FGEN) share price today is $0.4899

Can Indians buy FibroGen Inc shares?

Yes, Indians can buy shares of FibroGen Inc (FGEN) on Vested. To buy FibroGen Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in FGEN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of FibroGen Inc be purchased?

Yes, you can purchase fractional shares of FibroGen Inc (FGEN) via the Vested app. You can start investing in FibroGen Inc (FGEN) with a minimum investment of $1.

How to invest in FibroGen Inc shares from India?

You can invest in shares of FibroGen Inc (FGEN) via Vested in three simple steps:

  • Click on Sign Up or Invest in FGEN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in FibroGen Inc shares
What is FibroGen Inc 52-week high and low stock price?

The 52-week high price of FibroGen Inc (FGEN) is $2.93. The 52-week low price of FibroGen Inc (FGEN) is $0.18.

What is FibroGen Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of FibroGen Inc (FGEN) is 53.83

What is the Market Cap of FibroGen Inc?

The market capitalization of FibroGen Inc (FGEN) is $49.37M

What is FibroGen Inc’s stock symbol?

The stock symbol (or ticker) of FibroGen Inc is FGEN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top